Trial Profile
A multicentre study using the chemotherapy combination of bi-monthly Xeloda [capecitabine] and Eloxatin [oxaliplatin], with the addition of Avastin [bevacizumab] in patients with advanced colorectal cancer.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jun 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms XEN
- 02 Apr 2009 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
- 04 Oct 2006 New trial record.